Who Should Consider Active Surveillance?

Affiliations

Editorial

Peter Albertsen. J Urol. 2016 Dec.

. 2016 Dec;196(6):1604-1605.

doi: 10.1016/j.juro.2016.09.068. Epub 2016 Sep 15.

No abstract available

Comment on

Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols.
Komisarenko M, Timilshina N, Richard PO, Alibhai SM, Hamilton R, Kulkarni G, Zlotta A, Fleshner N, Finelli A. Komisarenko M, et al. J Urol. 2016 Dec;196(6):1645-1650. doi: 10.1016/j.juro.2016.06.083. Epub 2016 Jun 24. J Urol. 2016. PMID: 27350077
Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A. Musunuru HB, et al. J Urol. 2016 Dec;196(6):1651-1658. doi: 10.1016/j.juro.2016.06.102. Epub 2016 Aug 26. J Urol. 2016. PMID: 27569437